Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DTIL vs AKTS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DTIL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

DTIL Overall Winner 6-Pillar Tally: DTIL 5 – 0 AKTS (1 Tie) Matrix Metrics: DTIL 9 – 1 AKTS

As of Nov 16, 2026, Precision BioSciences, Inc. (DTIL) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DTIL carries a Unified Composite Score of 41.0/100 (SELL) at $7.38 (11.8x Forward P/E, -80.3% operating margin), whereas AKTS carries 30.6/100 (SELL) at $16.55 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although DTIL compares more favorably head-to-head, both DTIL (41.0/100 SELL) and AKTS (30.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: DTIL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.1); meanwhile AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DTIL vs AKTS
DTIL NASDAQ Head-to-Head Winner
Precision BioSciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.38
-2.38% 1D
Market Cap $306.9M
TTM Revenue $45M
Forward P/E 11.8x
Beta / 30D Vol 0.33β · 126% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 15.0 Fund 43.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.6%) with fading momentum, RSI 48
RSI-14: 48.1 · SMA20: $7.79 · SMA50: $7.02
AKTS US Equity
AKTS
Institutional Equity
$16.55
-0.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 67% Vol
Unified Composite Score
30.6 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $16.12 · SMA50: $18.33

6-Pillar Scorecard Institutional Category Breakdown (DTIL 5 – 0 AKTS)

Columns: Metric · DTIL · AKTS
1. Valuation Multiples DTIL
Forward P/E 11.8x N/M
Trailing P/E 32.2x N/M
PEG Ratio N/M N/M
EV / Revenue 5.6x N/M
2. Growth & Scale DTIL
Revenue Growth (YoY) +37272.4% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $45M N/A
Market Cap $306.9M N/A
3. Profitability & Quality DTIL
Gross Margin 100.0% N/A
Operating Margin -80.3% N/A
Net Profit Margin -85.6% N/A
Return on Equity (ROE) -115.3% N/A
4. Balance Sheet & Cash Flow DTIL
Cash Generation (TTM) -$52M N/A
Cash Flow Margin -116.4% N/A
Net Cash / Leverage $54M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DTIL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 112.8% (14th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DTIL (9) vs AKTS (1)
Institutional Metric DTIL AKTS Criterion Row Edge
Market Capitalization
Scale
$306.9M N/A Larger Scale DTIL
Trailing P/E Ratio
Valuation
32.2x N/M Lower Multiple DTIL
Forward P/E Ratio
Valuation
11.8x N/M Lower Multiple DTIL
Revenue Growth (YoY)
Growth
+37272.4% N/A Higher Growth DTIL
Operating Margin (TTM)
Profitability
-80.3% N/A Higher Margin DTIL
Net Profit Margin
Profitability
-85.6% N/A Higher Margin DTIL
Return on Equity (ROE)
Capital Efficiency
-115.3% N/A Higher ROE DTIL
52-Week Range Position
Momentum
50% ($4–$11) 13% ($14–$34) Stronger Trend DTIL
Beta / 30D Volatility
Risk Regime
0.33β · 126% Vol 1.35β · 67% Vol Lower Realized Risk AKTS
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 30.6 / 100 (SELL) Higher Composite DTIL
Trailing 12M Revenue (USD)
Operating Scale
$45M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$52M ($54M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DTIL +18.1 pp
DTIL: +27.99% · AKTS: +9.89%
3M Horizon DTIL +23.53 pp
DTIL: -10.27% · AKTS: -33.8%
6M Horizon DTIL +17.18 pp
DTIL: +6.11% · AKTS: -11.07%
1Y Horizon DTIL +114.51 pp
DTIL: +88.39% · AKTS: -26.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DTIL vs AKTS. Trailing 12-month operating profitability (DTIL -80.3% vs AKTS N/A) and valuation multiples (DTIL 11.8x vs AKTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DTIL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross Margin100.0%
Op. Margin-80.3%
ROE / Fwd P/E-115.3% · 11.8x
AKTS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DTIL CONSOLIDATION
129d in phase · OBV NEUTRAL
Current IV 112.8%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DTIL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKTS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DTIL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $306.9M market capitalization and -80.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AKTS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DTIL vs AKTS Key Questions & Quantitative Answers

As of Nov 16, 2026, Precision BioSciences, Inc. (DTIL) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DTIL carries a Unified Composite Score of 41.0/100 (SELL) at $7.38 (11.8x Forward P/E, -80.3% operating margin), whereas AKTS carries 30.6/100 (SELL) at $16.55 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although DTIL compares more favorably head-to-head, both DTIL (41.0/100 SELL) and AKTS (30.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: DTIL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.1); meanwhile AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DTIL leads the Growth & Scale pillar: DTIL posts +37272.4% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (100.0% gross margin, -80.3% operating margin), compared with AKTS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, DTIL generates $45M in USD-normalized revenue versus N/A for AKTS. In operating R&D and SG&A reinvestment, DTIL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKTS.

DTIL screens cheaper on headline valuation multiples. DTIL trades at 11.8x Forward P/E, 32.2x Trailing P/E, N/M PEG, and 5.6x EV/Revenue (-116.4% FCF margin), whereas AKTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DTIL (-115.3% ROE) versus AKTS (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, DTIL carries 112.8% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.33β · 126% Vol realized risk). By comparison, AKTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.